619-417-7506 Contact

Viloxazine (Qelbree): A Faster Strattera?

Joshua D. Feder, M.D. Blog Viloxazine (Qelbree): A Faster Strattera?

On April 2, 2021, viloxazine, brand name Qelbree, received FDA approval for the treatment of ADHD in children and adolescents ages 6-17 years old. The latest issue of The Carlat Child Psychiatry Report includes a News of Note covering this newly approved medication for ADHD. In this podcast, we discuss the advantages and disadvantages of viloxazine for children and adolescents with ADHD.

https://www.thecarlatreport.com/podcast/viloxazine-qelbree-a-faster-strattera-2/

 

Author
Joshua Feder, M.D. Dr. Feder's Blog

You Might Also Enjoy...

Improving Sleep in Children and Adolescents
We are in the midst of "The Great Sleep Recession." How can we enhance the quality of sleep in children and adolescents? Mara and I dive into sleep on this episode of The Carlat Psychiatry Podcast.

Assessing Sensorsy Processing Problems
Difficulties in sensory processing can profoundly impact quality of life. In this podcast, Mara and I will discuss how providers can identify sensory challenges to address these barriers and provide effective care in teens and adolescents.

Addressing Sensory Processing Challenges
Difficulties in sensory processing can profoundly impact quality of life. In this podcast, Mara and I will discuss how providers can identify sensory challenges to address these barriers and provide effective care in teens and adolescents.